Omnicell

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Santa Clara, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Omnicell reports robust Q4 earnings, eyes Advanced Services growth

Omnicell's Q4 2022 earnings call highlighted a strong financial performance, cost-saving initiatives, and strategic priorities for 2023. The company aims to drive growth through Advanced Services expansion, while navigating challenges such as market conditions and regulatory impacts. By focusing on operational efficiency and prudent financial management, Omnicell positions itself for sustainable growth and profitability.

Omnicell surpasses Q1 revenue targets, eyes automation for growth

Omnicell's Q1 2023 earnings call showcased robust financial performance, strategic partnerships, and cost containment efforts. The company is well-positioned to capitalize on the growing demand for automation in healthcare.

Omnicell surpasses Q2 expectations, focuses on AI strategy growth

Omnicell's Q2 performance exceeded expectations, driven by strong revenues and margins.
The company's strategic strengths lie in customer wins, AI focus, and margin management.
Challenges include market dynamics and the need for ongoing adjustments.
Opportunities for growth include raised guidance, AI strategy development, and CMS impact.

Omnicell reports Q3 earnings, faces challenges but eyes growth opportunities

Omnicell's Q3 2023 performance reflects solid total revenues, EBITDA, and EPS, with market challenges impacting bookings and product lines. The company's strengths include customer wins, profitability, and strategic growth initiatives.
Challenges include revenue impact from reduced bookings, point-of-care revenue decline, and pipeline deal deferrals. Opportunities exist in Advanced Services growth, market expansion, and cost management strategies.
Omnicell's focus on profitability, revenue growth, and customer value delivery positions it for future success. The company's strategic actions and financial outlook indicate a proactive approach to addressing challenges and seizing opportunities.

Omnicell reports Q4 revenue decline but sees growth opportunities ahead

Omnicell's Q4 2023 performance saw revenue decline but highlighted strategic wins and a focus on operational optimization.
The company's strengths lie in customer engagement, product upgrades, and expansion into new markets.
Challenges include industry costs and regulatory hurdles, but opportunities exist in market growth and service enhancements.
Overall, Omnicell remains optimistic about future demand and revenue potential, with a conservative outlook for Q1.

Omnicell surpasses Q1 revenue targets, exits product line for value

Omnicell's Q1 2024 earnings call showcased strong performance exceeding guidance, with a focus on cost management and strategic initiatives. The company announced plans to exit an international product line to improve shareholder value. Opportunities lie in the growth of the XT Amplify program and EnlivenHealth brand, despite challenges in revenue decline and operational decisions.

Omnicell reports robust Q3 earnings, eyes growth in healthcare solutions

Omnicell's Q3 2024 performance reflects strong revenue growth and operational resilience in healthcare solutions.
The company's strategic focus on customer-centricity and innovation positions it for sustained success.
Challenges in product revenue timing and cost optimization require ongoing attention for operational efficiency.
Opportunities in expanding services and market positioning offer avenues for future growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Fort Worth, TX.

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Release Fourth Quarter and Full Year 2023 Financial Results on February 8, 2024.

Omnicell to Release Fourth Quarter and Full Year 2023 Financial Results on February 8, 2024

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Elects Eileen Voynick to Board of Directors.

Omnicell Elects Eileen Voynick to Board of Directors

Omnicell (OMCL) plans to focus on integrating customer success functions into its broader organizational structure.

Omnicell (OMCL) Gains From Innovation Amid Cost Pressure

Omnicell (OMCL) accelerates a shift to cloud-based solutions and tech-enabled services through the launches of Inventory Optimization Service and Central Pharmacy Dispensing Services.

Omnicell's (OMCL) Global Expansion Strong, Macro Issues Ail

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Present at the Piper Sandler 35th Annual Healthcare Conference.

Omnicell to Present at the Piper Sandler 35th Annual Healthcare Conference

Omnicell (OMCL) accelerates its shift to cloud-based solutions and tech-enabled services through the launch of Inventory Optimization Service and Central Pharmacy Dispensing Services.

Omnicell's (OMCL) Portfolio Expansion Aids Amid Macro Woes

Omnicell, Inc. (NASDAQ:OMCL ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Kathleen Nemeth - SVP of IR Randall Lipps - Chairman, President, CEO and Founder Nchacha Etta - EVP and CFO Conference Call Participants Stan Berenshteyn - Wells Fargo Scott Schoenhaus - KeyBanc Jes Tassan - Piper Sandler David Larsen - BTIG Jack Siedow - Craig-Hallum Bill Sutherland - The Benchmark Company Operator Good morning, my name is Jordan, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Omnicell Third Quarter Earnings Call.

Omnicell, Inc. (OMCL) Q3 2023 Earnings Call Transcript

Privia Health Group

Investors interested in Medical Info Systems stocks are likely familiar with Omnicell (OMCL) and Privia Health (PRVA). But which of these two companies is the best option for those looking for undervalued stocks?

OMCL vs. PRVA: Which Stock Should Value Investors Buy Now?

Omnicell's (OMCL) third-quarter 2023 results reflect operational discipline in a weak demand environment.

Omnicell (OMCL) Q3 Earnings and Revenues Beat, Margins Down

FORT WORTH, Texas--(BUSINESS WIRE)--Baptist Health Engages Omnicell in an Effort to Enhance Pharmacy Care and Further Gain Control of Medication Supply Chain.

Baptist Health Engages Omnicell in an Effort to Enhance Pharmacy Care and Further Gain Control of Medication Supply Chain

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Announces Third Quarter 2023 Results; Updates Fiscal Year 2023 Guidance and Announces Reduction in Force.

Omnicell Announces Third Quarter 2023 Results; Updates Fiscal Year 2023 Guidance and Announces Reduction in Force

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Release Third Quarter 2023 Financial Results on November 2, 2023.

Omnicell to Release Third Quarter 2023 Financial Results on November 2, 2023

Investors are optimistic about Omnicell (OMCL), led by its digital transformation strategy.

Here's Why Investors Should Retain Omnicell (OMCL) Stock Now

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Present at the 2023 Wells Fargo Healthcare Conference.

Omnicell to Present at the 2023 Wells Fargo Healthcare Conference

Omnicell Inc ( OMCL , Financial), a prominent player in the Healthcare Providers & Services industry, is currently trading at $64.36 with a market capitalization of $2.9 billion. The stock has seen a gain of 4.31% today, despite a loss of 13.52% over the past four weeks.

Omnicell Inc: A Healthcare Stock with Good Outperformance Potential

Omnicell's (OMCL) second-quarter 2023 performance reflects strength in advanced services and technical services as well as continued strong execution.

Omnicell (OMCL) Q2 Earnings and Revenues Top, '23 View Raised

Omnicell, Inc. (NASDAQ:OMCL ) Q2 2023 Earnings Conference Call August 1, 2023 4:30 PM ET Company Participants Kathleen Nemeth - Head of IR Randall Lipps - Chief Executive Officer Nchacha Etta - EVP and Chief Financial Officer Conference Call Participants Scott Schoenhaus - KeyBanc Allen Lutz - Bank of America Stan Berenshteyn - Wells Fargo Matt Hewitt - Craig Hallum Capital Group Bill Sutherland - the Benchmark Company David Larsen - BTIG Jessica Tassan - Piper Sandler Operator Good afternoon and welcome everyone to the Omnicell Second Quarter 2023 Financial Results Call. Please note that this call is being recorded.

Omnicell, Inc. (OMCL) Q2 2023 Earnings Call Transcript

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Announces Second Quarter 2023 Results.

Omnicell Announces Second Quarter 2023 Results

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Release Second Quarter 2023 Financial Results on August 1, 2023.

Omnicell to Release Second Quarter 2023 Financial Results on August 1, 2023

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Appoints Bobby Ghoshal to Board of Directors.

Omnicell Appoints Bobby Ghoshal to Board of Directors

Sanchez, Who Joined EmpiRx Health Earlier this Year as President, Assumes CEO Role – Reinforces Commitment to Company's Healthcare Mission MONTVALE, N.J. , June 1, 2023 /PRNewswire/ -- EmpiRx Health, the industry's only value-based PBM, today announced that the company's president, Danny Sanchez, has been named Chief Executive Officer.

EmpiRx Health Names Healthcare and Technology Veteran Danny Sanchez as CEO

Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock?

Why Is Omnicell (OMCL) Up 9.7% Since Last Earnings Report?

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Announces Leadership and Organizational Changes.

Omnicell Announces Leadership and Organizational Changes

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Appoints Nchacha E. Etta as Executive Vice President and Chief Financial Officer.

Omnicell Appoints Nchacha E. Etta as Executive Vice President and Chief Financial Officer

Omnicell (OMCL) remains well-positioned to meet pharmacy and hospital needs, backed by the recent acquisitions and expansion of its advanced services solutions.

News for Omnicell Stock (OMCL)